公开(公告)号：US20160002307A1

公开(公告)日：2016-01-07

申请号：US14799532

申请日：2015-07-14

申请人： The Government of the United States of America as represented by the Secretary of the Department of ,  The Progeria Research Foundation, Inc. ,  Research Foundation for Mental Hygiene, Inc.

发明人： B. Maria H. Eriksson ,  Francis S. Collins ,  Leslie B. Gordon ,  William Ted Brown

IPC分类号： C07K14/47

CPC分类号： C07K14/47 ,  C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N2500/04 ,  Y10T436/143333

摘要： Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is 50 amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), methods of treating such conditions, methods of selecting treatments, methods of screening for compounds that influence Lamin A activity, and methods of influencing the expression of LMNA or LMNA variants are also described. Oligonucleotides and other compounds for use in examples of the described methods are also provided, as are protein-specific binding agents, such as antibodies, that bind specifically to at least one epitope of a Lamin A variant protein preferentially compared to wildtype Lamin A, and methods of using such antibodies in diagnosis, treatment, and screening. Also provided are kits for carrying out the methods described herein.

摘要翻译： 本文公开了导致HGPS的LMNA基因中的点突变。 这些突变激活LMNA基因内的隐性剪接位点，导致部分外显子11的缺失和产生比正常蛋白短50个氨基酸的突变Lamin A蛋白产物。 除了新型Lamin A变体蛋白和编码该变体的核酸之外，使用这些分子检测与受试者的LMNA突变相关的生物学条件（例如，HGPS，动脉硬化和其他与年龄有关的疾病）的方法， 还描述了治疗这些病症，选择治疗方法，筛选影响Lamin A活性的化合物的方法，以及影响LMNA或LMNA变体表达的方法。 还提供了用于所述方法的实施例的寡核苷酸和其它化合物，以及优选与野生型Lamin A相比特异性结合Lamin A变体蛋白的至少一个表位的蛋白质特异性结合剂，例如抗体，以及 在诊断，治疗和筛查中使用这些抗体的方法。 还提供了用于实施本文所述方法的试剂盒。

公开(公告)号：US20140072973A1

公开(公告)日：2014-03-13

申请号：US14025497

申请日：2013-09-12

申请人： The Government of the United States of America as represented by the Secretary of the Department of ,  Research Foundation for Mental Hygiene, Inc. ,  The Progeria Research Foundation, Inc.

发明人： B. Maria H. Eriksson ,  Francis S. Collins ,  Leslie B. Gordon ,  William Ted Brown

IPC分类号： C12Q1/68

CPC分类号： C07K14/47 ,  C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N2500/04 ,  Y10T436/143333

摘要： Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is 50 amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), methods of treating such conditions, methods of selecting treatments, methods of screening for compounds that influence Lamin A activity, and methods of influencing the expression of LMNA or LMNA variants are also described. Oligonucleotides and other compounds for use in examples of the described methods are also provided, as are protein-specific binding agents, such as antibodies, that bind specifically to at least one epitope of a Lamin A variant protein preferentially compared to wildtype Lamin A, and methods of using such antibodies in diagnosis, treatment, and screening. Also provided are kits for carrying out the methods described herein.

摘要翻译： 本文公开了导致HGPS的LMNA基因中的点突变。 这些突变激活LMNA基因内的隐性剪接位点，导致部分外显子11的缺失和产生比正常蛋白短50个氨基酸的突变Lamin A蛋白产物。 除了新型Lamin A变体蛋白和编码该变体的核酸之外，使用这些分子检测与受试者的LMNA突变相关的生物学条件（例如，HGPS，动脉硬化和其他与年龄有关的疾病）的方法， 还描述了治疗这些病症，选择治疗方法，筛选影响Lamin A活性的化合物的方法，以及影响LMNA或LMNA变体表达的方法。 还提供了用于所述方法的实施例的寡核苷酸和其它化合物，以及优选与野生型Lamin A相比特异性结合Lamin A变体蛋白的至少一个表位的蛋白质特异性结合剂，例如抗体，以及 在诊断，治疗和筛查中使用这些抗体的方法。 还提供了用于实施本文所述方法的试剂盒。

公开(公告)号：US09115400B2

公开(公告)日：2015-08-25

申请号：US14025497

申请日：2013-09-12

申请人： The United States of America as represented by the Secretary of the Department of Health and Human Services ,  The Progeria Research Foundation, Inc. ,  Research Foundation for Mental Hygiene, Inc.

发明人： B. Maria H. Eriksson ,  Francis S. Collins ,  Leslie B. Gordon ,  William Ted Brown

IPC分类号： C07H21/04 ,  C07K14/47 ,  C12Q1/68

CPC分类号： C07K14/47 ,  C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N2500/04 ,  Y10T436/143333

摘要： Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is 50 amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), methods of treating such conditions, methods of selecting treatments, methods of screening for compounds that influence Lamin A activity, and methods of influencing the expression of LMNA or LMNA variants are also described. Oligonucleotides and other compounds for use in examples of the described methods are also provided, as are protein-specific binding agents, such as antibodies, that bind specifically to at least one epitope of a Lamin A variant protein preferentially compared to wildtype Lamin A, and methods of using such antibodies in diagnosis, treatment, and screening. Also provided are kits for carrying out the methods described herein.

摘要翻译： 本文公开了导致HGPS的LMNA基因中的点突变。 这些突变激活LMNA基因内的隐性剪接位点，导致部分外显子11的缺失和产生比正常蛋白短50个氨基酸的突变Lamin A蛋白产物。 除了新型Lamin A变体蛋白和编码该变体的核酸之外，使用这些分子检测与受试者的LMNA突变相关的生物学条件（例如，HGPS，动脉硬化和其他与年龄有关的疾病）的方法， 还描述了治疗这些病症，选择治疗方法，筛选影响Lamin A活性的化合物的方法，以及影响LMNA或LMNA变体表达的方法。 还提供了用于所述方法的实施例的寡核苷酸和其它化合物，以及优选与野生型Lamin A相比特异性结合Lamin A变体蛋白的至少一个表位的蛋白质特异性结合剂，例如抗体，以及 在诊断，治疗和筛查中使用这些抗体的方法。 还提供了用于实施本文所述方法的试剂盒。